Does Lilly have enough on Alzheimer's drug?

Back to TopCommentsE-mailPrintBookmark and Share

After Eli Lilly and Co. found a “glimmer of hope” in its test of its experimental Alzheimer’s drug, doctors and stock analysts generally concluded the company needs to conduct another long clinical trial to prove the drug’s effect.

But one stock analyst thinks Lilly already has what it needs to ask for approval for its drug.

Catherine Arnold, a pharmaceutical analyst at Credit Suisse in New York, said it’s at least “plausible” that Lilly would file for market approval of the drug, solanezumab, which around the halls of Lilly’s Indianapolis headquarters is known simply as “sola.”

“Filing is plausible for sola given company’s announcement that cognitive benefits were achieved in the mild [Alzheimer’s population], assuming biomarker data is consistent,” Arnold dashed off in an Aug. 24 research note, shortly after Lilly released clinical trial results for sola that showed “statistically significant” slowing of cognitive decline in patients with a mild form of Alzheimer’s disease.

By biomarker data, Arnold means the results of blood and spinal fluid tests that Lilly has done with patients taking sola. In earlier trials, patients taking the drug showed higher levels of molecules made up sola and the amyloid protein, which sola is designed to clear out of the brain.

Alzheimer’s disease appears to be caused, at least in part, by excessive production or failure to clear away amyloid in the brain. The amyloid proteins stick together easily, forming clumps and then plaques, either of which can block the functioning of neurons.

The brain’s neurons eventually die and patients’ brains start losing memory and, eventually, their ability to control basic motor functions.

Also, Lilly used brain scans of patients to see if the size of amyloid plaques in patients’ brains were affected by sola.

Arnold bases her prediction on previous comments by Dr. Russell Katz, director of the division of neurology products at the U.S. Food and Drug Administration. In an interview in April, Katz was asked if the FDA would approve an Alzheimer’s drug that showed “a subtle clinical change in conjunction with an effect on a surrogate or even multiple surrogate markers.”

The phrase “surrogate markers” is synonymous with biomarkers, and refers to quantifiable tests of blood, fluids or imaging scans.

Katz’s response? “Yes, we are open to that.”

Based partly on this hope, Arnold raised her rating on Lilly and her expectations for its stock price. She predicts it will hit $53 per share soon, up from her previous prediction of $41 per share.

Sola would be enormously lucrative for Lilly because there are no drugs on the market that slow the progress of Alzheiemer’s disease. Arnold estimates Lilly could charge $7,000 per patient per year for the drug in the United States, and $5,200 per patient per year in Europe.

If taken only by mild patients, which make up about 40 percent of the 18 million people worldwide who suffer from Alzheimer’s disease, Arnold predicts the drug could reach $3.5 billion in sales by 2020.

Other analysts, who think in the absence of other options that the first drug on the market will be given to all manner of Alzheimer’s patients, predict sola could reach $9 billion in annual sales.

But most think Lilly will have to spend more time and money before it truly has a shot at those sales. Another Phase 3 clinical trial would likely cost more than $100 million, according to research by the Tufts Center on Drug Development.

“Lilly will likely have to do another Phase-3 trial, most likely in just mild patients or earlier who are more likely to respond,” BMO Capital Markets analyst Alex Arfaei wrote in an Aug. 24 research note. “Sola is most likely not dead, but it is likely delayed to 2017-2018 and will likely be applicable to a smaller subset of AD patients.”

Doctors interviewed about sola sounded similar thoughts.

“I take care of people with Alzheimer’s disease who desperately want to see something positive here,” Dr. David Knopman, a neurologist at Mayo Clinic in Rochester, Minn., told Bloomberg News. “For my patients right now, absolutely it won’t be available commercially. I don’t want them thinking this is something being withheld by a ‘nasty’ Food and Drug Administration, or that the scientists are being too cautious. This was a negative study.”

Indeed, Lilly’s studies of sola in 2,050 patients in 16 countries failed their primary goals of slowing Alzheimer’s disease in both mild and moderate patients. Also, Lilly found no slowing, even among mild patients taking sola, in their declining ability to do daily activities, which is another key impact of Alzheimer’s disease.

Lilly has given its raw data from the sola trials to academic researchers, who will announce their own conclusions on Oct. 8 at a conference of the American Neurological Association. In the meantime, Lilly officials will begin conversations with regulators at the FDA and at similar authorities in other countries.

But Lilly officials remain mum on whether they will ask for market approval or do another study.

Dave Ricks, president of Lilly’s Bio-medicines business unit, said Lilly has not given up on sola and in fact feels like the drug is a lot less risky now than most thought it was.

“I personally think the risk is different today than it was on Wednesday,” Ricks said Aug. 24 at Lilly’s headquarters. He also said the positive signal from sola reaffirms Lilly’s strategy of pursuing some high-risk medicines—even though its recent record of launching new drugs has not been stellar.

“Our overall mood, we feel good. We feel good in our overall strategy,” Ricks said.



Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Good Day I am Mr (Victoria Wright) from United state of America, i stayed in NEW YORK, and i have a broke up business, until i found this company email who help me to gain a loan for business,, and now i want to used this short medium to congratulate the below company for the fast and safe money they loan to me without any form of collateral, i loan 500,000USD from the company to save my business and lots more, i saw their mail on the internet, everyone always give testimony for what they did, so i quickly contacted them and they all did everything for me without stress and my money was sent to my account just 3 days later, i was surprise and i feel so glad, now i have a standard business control agent who help me, now i will advice those who need urgent loan to contact him at the bellow email:zenithfirm12@gmail.com

  2. NOTICE:This is to inform the general public that Vampires are real. My name is James Franklyn.,am an agent of vampire,am here to introduce our new world trend to you,a world of vampire where life get easier,we have made so many persons vampires and have turned them rich,you will be assured long life and prosperity,you shall be made to be very sensitive to mental alertness,stronger and also very fast,you will not be restricted to walking at night only even at the very middle of broad day light you will be made to walk.In case you are wildly oppressed by some unscrupulous persons we can still help you fight them.Your protection is assured immediately you join.Just contact the bellow email if you are interested we are here to attend to you anytime you want us. Contact the bellow email for more details. Email:vampirescreed@hotmail.com Sincerely: James Franklyn.

  3. Bravo! Someone else that is willing to speak the truth! Bravo!_____NBCSN is available in almost 2 MILLION more homes than just a few years ago, but Indycar STILL gets less total viewers than it did just a few years ago when NBC took over Versus. Attendance and ratings cratered with the end of season races (just when the title battle got "interesting" HAH!__________And now...new race in Basilia, where Miles celebrated the "rich history" of Indycar racing there. Rich history? What, 7 events in the 100 years of AOW? Yep, some history. Well, at least its an oval. It's not??? Are you kidding me??? Gosh darn road racin furriners.

  4. PURITY RAY LOAN OFFER........ Have you been denied by your banks,or are you in need of of an urgent loan to pay of your bills we are capable of giving loans @ cheaper rate to interested individuals, student, companies and members of the public in need of finance to settle bills, we do offer considerable loans which you can count on. For more information on our various types of loan,then you will have to contact PURITY RAY LOAN FIRM, to help you achieve your desire LOAN APPLICATION FORM TO BE FILLED BORROWERS INFORMATION * Full name:………………………. * SEX * ……………………………. * Country………………………….. * State:……………………………. * Land:…………………………….. * Occupation:…………………….. * phone number:…………………. * Telephone: ………………………….. * Age:………………………………. * Amount needed as loan:……… * Loan Duration:………………….. * Propose of Loan:……………….. * Annual revenue:………………… * Monthly Income:……………….. * Guarantee:………………………. * Payment: monthly or annually Email.....purityrayloanfirm@gmail.com Thank you and God bless Mr Purity Ray PURITY RAY LOAN FIRM we tend to serve you better

  5. Problem: most of the people responding to this article don't know about this service AT ALL! Why? Lack of awareness. This isn't IndyGo. This is CIRTA: might as well be the mattress company because they are asleep at the wheel - something like 3 directors over the last year? Playing with federal grant money is great! This "region" wants commuter rail service, has spent MILLIONS on Transportation studies yet can't even support a commuter bus line? This is largely for suburban riders to get to downtown - not for "service people to work in our hotels and restaurants" ! Get your head out of your backside!! These are professionals, students etc. that don't want to fight traffic, save some money on parking, gas, stress.... if CIRTA would put their federal money into widely promoting the sevive to Greenwood, Fishers & Carmel instead of finding directors and studies - this would be a successful service. Our family uses(d) it daily for the last several years - but the recent uncertainty & now unreliability due to cuts from Carmel has been a problem. Now, costs us an additional $350/month for gas & parking ( $4200/year) plus vehicle wear, service, environmental impact ... YES - this REGION needs this this type of service in order to keep growing and getting the people it needs to fill skilled positions in downtown Indianapolis. Think outside of your own car !!!